  |
|
03.09.2010 OvPlex™
launched in Asia |
|
HealthLinx
Limited
Singapore
distribution partner INEX Innovation Exchange
Pte Ltd has launched OvPlex™ in Singapore
yesterday. Under the terms of its
agreement with HealthLinx, INEX will have the
exclusive rights to market, sell and distribute
OvPlex™
for a period
of ten years. Singapore will serve as the
platform to launch into the region including
India, Malaysia, Thailand, Indonesia and
Vietnam.
 |
 |
|
|
|
|
|
|
|
30.08.2010
BNC210 Data Presented at
Leading European Forum |
|
Bionomics Limited
(ASX: BNO)
today
announced the presentation of preclinical and
clinical data for its anti-anxiety compound
BNC210 at the annual European College of
Neuropsychopharmacology (ECNP)
conference in Amsterdam. The data presented
demonstrates preclinical and clinical attributes
of BNC210 that provide further support for its
development for the treatment of anxiety and
depression.
|
 |
|
|
|
|
|
|
|
24.08.2010
Phosphagenics Appoints Three New Non-Executive Directors
to Boost its Commercial
Transformation |
|
Phosphagenics Limited
(“Phosphagenics”)
(ASX: POH; OTCQX: PPGNY)
has appointed Mr Stuart James, Dr Sandra Webb and Mr Don Clarke as
Non-Executive Directors to formulate and facilitate the
implementation of strategies to commercialise the company’s research
and development pipeline.
All new Directors have senior commercial experience and align with
Phosphagenics’ transition from product development to product
distribution and sales.
|
 |
|
|
|
|
|
|
|
18.08.2010
Phylogica to Pursue
Antimicrobial Peptide Discovery Through Licensing Agreement with
MedImmune |
|
Phylogica Ltd
(ASX: PYC, XETRA: PH7), a
public Australian drug discovery company,
announced today that they have entered into an
agreement with MedImmune to evaluate Phylogica’s
proprietary Phylomer®
peptide library for novel antimicrobial
peptides. The agreement
between MedImmune, the worldwide biologics unit
of AstraZeneca PLC, and Phylogica establishes a
plan for collaborative discovery between the
companies, with potential development and
commercialization of resulting novel antibiotics
by MedImmune.
|
 |
|
|
|
|
|
|
|
06.08.2010
Genetic
Technologies grants third license to Monsanto |
|
Genetic Technologies Limited
(ASX:GTG; NASDAQ: GENE)
is pleased to
announce that it has granted a third license to
Monsanto Company of St. Louis, Missouri, USA
(“Monsanto”).
Genetic
Technologies had previously granted a
non-exclusive license to the GTG non-coding
patents to Monsanto in 2007 for all applications
in plants and plant products. Soon after, GTG
also granted Monsanto a further non-exclusive
license for applications in swine. The current
license now grants Monsanto similar rights for
cattle. The commercial terms of this further
license are covered by formal confidentiality
provisions within the relevant Settlement and
License Agreement and therefore cannot be
disclosed.
|
 |
|
|
|
|
|
|
|
30.07.2010 Abraxis
Bioscience and Specialised Therapeutics Announce
Approval to Market Abraxane for Metastatic Breast
Cancer in New Zealand |
|
Abraxis BioScience,
Inc. (NASDAQ:ABII), a fully integrated, global
biotechnology company, and
Specialised Therapeutics Ltd.
today announced that MEDSAFE, the New Zealand Medicines and Medical
Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle
albumin-bound paclitaxel) for the treatment of metastatic breast
cancer after failure of anthracycline therapy.
|
 |
|
|
|
|
|
|
|
22.06.2010
Genetic Technologies appoints
Lewis J. Stuart as General Manager of its New North American
Molecular Diagnostics Business |
|
Genetic Technologies Limited
(ASX:GTG; NASDAQ: GENE)
has executed a Settlement
and License Agreement with respect to its non-coding patents with
EraGen Biosciences Inc. (“EraGen”), based in Madison, Wisconsin,
USA. This is the second such agreement that GTG has secured in
the last week.
|
|
|
|
|
|
|
|
|
21.06.2010 HealthLinx continues
global rollout with Ethics Approval in South Korea for OvPlex™ Study |
|
HealthLinx
Limited
(ASX:HTX) has taken a
major step forward towards the launch of its OvPlex™ ovarian cancer
diagnostic in South Korea with a new agreement on an imminent 220
patient biomarker trial for OvPlexTM.
The study in South Korea is a prerequisite for the test receiving
product approval by the South Korea Food and Drug Administration
(KFDA).
|
|
|
|
|
|
|
|
|
15.06.2010
Victorian Government Delivers
$750,000 for International Study Into OvPlex™ Ovarian Cancer Test |
|
The
Victorian Government is backing a multi-million
dollar trial into a new generation OvPlex™ test
that will target the earlier detection of
ovarian cancer, developed in Melbourne by
biotechnology company
HealthLinx Ltd.
|
|
|
|
|
|
|
|
|
15.06.2010 Major International Study
Begins on OVPLEX™ Ovarian Cancer Test |
|
Melbourne
biotechnology company
HealthLinx Ltd
(ASX:HTX)
will today launch a major international trial on
the OvPlex™ test, that will see 1150 samples
screened using the current five (5) biomarker
panel and an additional two (2) biomarkers
including the recently described biomarker AGR2.
|
|
|
|
|
|
|
|
|
15.06.2010
Healthscope to Distribute OVPLEX™
Ovarian Cancer Test to Australian Market Higher Anticipated Sales,
Wider Distribution
|
|
HealthLinx
Limited
OvPlex™ ovarian cancer
diagnostic will be released in Singapore in
July making it the third
OvPlex™ launch in 12 months. INEX the
distribution partner has the rights to
distribute the superior diagnostic in Singapore,
Thailand, Vietnam, Malaysia, Indonesia and
India.
|
|
|
|
|
|
|
|
|
10.06.2010
US Recell Spray-on-Skin
Enrolment Commences |
|
Avita Medical:
In an important milestone for
Avita Medical the first United States-based treatment of a patient
with ReCell®
under the approved FDA
protocol was conducted. The treatment of a burns victim on 27 May
2010 was at Wake Forest University Baptist Medical Burn Center in
Winston-Salem, North Carolina.
|
 |
|
|
|
|
|
|
|
31.05.2010
China and Taiwan
Product Distribution Update |
|
Dr
William Dolphin, CEO
Avita Medical, and Ms
Lorraine Glover, GM Avita Asia Pacific recently
returned from meetings with key surgeons,
regulatory representatives and distributors in
China and Taiwan to advance sales and marketing
efforts for ReCell Spray-On-Skin in these
countries.
|
|
|
|
|
|
|
|
|
13.05.2010
US FDA meeting date set for
review of international Phase II melanoma trial |
|
The US Food and Drug
Administration (FDA) has confirmed a specialist panel will meet with
Viralytics on the 22nd June for a Pre-Investigational New Drug (IND)
meeting.
|
 |
|
|
|
|
|
|
|
10.05.2010
All of GTG’s Core Non-Coding DNA
Patent Claims Upheld in
Full by US Patent and Trademark Office |
|
Genetic Technologies Limited
(ASX:GTG; NASDAQ: GENE)
has received
formal notification from the United States Patent and Trademarks
Office (USPTO) that it has upheld, without amendment, all of the
claims which formed the basis of the re-examination action (ASX
announcement June 30th, 2009) of the Company’s core
5,612,179 (the “‘179”) non-coding deoxyribonucleic acid (DNA)
patent.
|
|
|
|
|
|
|
|
|
04.05.2010 Genetic Technologies
Grants Non-Coding License to EraGen Biosciences |
|
Genetic Technologies Limited
(ASX:GTG; NASDAQ: GENE)
has executed a Settlement
and License Agreement with respect to its non-coding patents with
EraGen Biosciences Inc. (“EraGen”), based in Madison, Wisconsin,
USA. This is the second such agreement that GTG has secured in
the last week.
|
|
|
|
|
|
|
|
|
03.05.2010
Genetic Technologies Grants
Non-Coding License to Gen-Probe |
|
Genetic Technologies Limited
(ASX:GTG; NASDAQ: GENE)
is pleased to announce that it has executed a
Settlement and License Agreement with respect to
its non-coding patents with Gen-Probe Inc.,
based in San Diego, California, USA. The license granted by
GTG covers the world-wide activities of
Gen-Probe in relation to its genetic diagnostics
and analysis products. The commercial
terms of the license granted to Gen-Probe are
subject to confidentiality between the parties.
|
|
|
|
|
|
|
|
|
29.04.2010 OVPLEX
to be Launched in Singapore in July |
|
HealthLinx
Limited
OvPlex™ ovarian cancer
diagnostic will be released in Singapore in
July making it the third
OvPlex™ launch in 12 months. INEX the
distribution partner has the rights to
distribute the superior diagnostic in Singapore,
Thailand, Vietnam, Malaysia, Indonesia and
India.
|
|
|
|
|
|
|
|
|
22.04.2010
Hunter Immunology: International
Medical Experts Recognise Benefit of Australian COPD Treatment |
|
A landmark trial into a new
treatment for patients with Chronic Obstructive Pulmonary Disease
(COPD) has shown positive results, with international medical
experts now recognising the treatment's promise.
|
|
|
|
|
|
|
|
|
21.04.2010
Max Planck Institute adopts
Gelcompany’s HPE System |
|
Gelcompany is pleased to
announce that Dr. Friedrich Lottspeich, the head
of the Protein Analysis Group within the world
renowned
Max
Planck-Institute of Biochemistry
has adopted our new HPE FlatTop Tower
System for his protein analysis work.
|
 |
|
|
|
|
|
|
|
14.04.2010 Genetic Technologies acquires
BREVAGen™ breast cancer risk test |
|
Genetic Technologies Limited
(ASX:GTG; NASDAQ: GENE) advises it has
acquired certain assets from US-based Perlegen Sciences, Inc. with
the main asset being the BREVAGen™ breast cancer risk test. In
addition to the BREVAGen™ test, GTG has acquired a suite of granted
patents valid to 2022 which augment and extend GTG’s current
non-coding patent portfolio.
|
|
All rights reserved